High-affinity peroxisome proliferator-activated receptor β/δ-specific ligands with pure antagonistic or inverse agonistic properties

Molecular Pharmacology

Volumn 80, Issue 5, 2011, Pages 828-838

  Naruhn, Simone ^a   Toth, Philipp M ^a   Adhikary, Till ^a   Kaddatz, Kerstin ^a   Pape, Veronika ^a   Dor̈r, Stefanie ^a   Klebe, Gerhard ^a   Mul̈ler Brus̈selbach, Sabine ^a   Diederich, Wibke E ^a   Mul̈ler, Rolf ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GSK 0660; METHYL 3 [N [4 (HEXYLAMINO) 2 METHOXYPHENYL]SULFAMOYL]THIOPHENE 2 CARBOXYLATE; METHYL 3 [N [4 (TERT BUTYLAMINO) 2 METHOXYPHENYL]SULFAMOYL]THIOPHENE 2 CARBOXYLATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PTS 58; ST 247; UNCLASSIFIED DRUG;

ANGPTL4 GENE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; DOWN REGULATION; DRUG SYNTHESIS; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

ANIMALS; BASE SEQUENCE; BINDING SITES; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; LIGANDS; MICE; PPAR DELTA; PPAR-BETA; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 80054786234     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.074039     Document Type: Article

References (55)

1. Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P, Hauser K, Hahnfeldt P, Hlatky L, Debus J, et al. (2007) Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA 104:12890-12895. (Pubitemid 47255250)
2. Adhikary T, Kaddatz K, Finkernagel F, Schönbauer A, Meissner W, Scharfe M, Jarek M, Blöcker H, Müller-Brüsselbach S, and Müller R (2011) Genome-wide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). PLoS One 6:e16344.
3. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, and Evans RM (2002) Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99:303-308. (Pubitemid 34060358)
4. Bedu E, Wahli W, and Desvergne B (2005) Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases. Expert Opin Ther Targets 9:861-873. (Pubitemid 41131684)
5. Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, Kang BH, Kennett MJ, Gonzalez FJ, and Peters JM (2008) Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis. Carcinogenesis 29:2406-2414.
6. Billin AN (2008) PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin Investig Drugs 17:1465-1471.
7. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, and Peters JM (2006) The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal 18:9-20. (Pubitemid 41415710)
8. Chapkin RS, Miller CC, Somers SD, and Erickson KL (1988) Ability of 15-hydroxyeicosatrienoic acid (15-OH-20:3) to modulate macrophage arachidonic acid metabolism. Biochem Biophys Res Commun 153:799-804.
9. Codina A, Love JD, Li Y, Lazar MA, Neuhaus D, and Schwabe JW (2005) Structural insights into the interaction and activation of histone deacetylase 3 by nuclear receptor corepressors. Proc Natl Acad Sci USA 102:6009-6014. (Pubitemid 40594246)
10. Davies JQ and Gordon S (2005) Isolation and culture of human macrophages. Methods Mol Biol 290:105-116.
11. Di-Poi N, Tan NS, Michalik L, Wahli W, and Desvergne B (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10:721-733. (Pubitemid 35335629)
12. Fauti T, Müller-Brüsselbach S, Kreutzer M, Rieck M, Meissner W, Rapp U, Schweer H, Kömhoff M, and Müller R (2006) Induction of PPARbeta and prostacyclin (PGI2) synthesis by Raf signaling: failure of PGI2 to activate PPARbeta. FEBS J 273:170-179.
13. Gehrke S, Jérôme V, and Müller R (2003) Chimeric transcriptional control units for improved liver-specific transgene expression. Gene 322:137-143. (Pubitemid 37485990)
14. Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA, and Shiekhattar R (2000) A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 14:1048-1057. (Pubitemid 30324419)
15. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, and DuBois RN (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10:245-247. (Pubitemid 38667613)
16. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, and Glass CK (1999) Interleukin-4-dependent production of PPARgamma ligands in macrophages by 12/15-lipoxygenase. Nature 400:378-382. (Pubitemid 29344205)
17. Jérôme V and Müller R (1998) Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum Gene Ther 9:2653-2659.
18. Kaddatz K, Adhikary T, Finkernagel F, Meissner W, Müller- Brüsselbach S, and Müller R (2010) Transcriptional profiling identifies functional interactions of TGFβ and PPARβ/δ signaling: synergistic induction of ANGPTL4 transcription. J Biol Chem 285:29469-29479.
19. Kanakasabai S, Chearwae W, Walline CC, Iams W, Adams SM, and Bright JJ (2010) Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 130:572-588.
20. Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, Hatano B, and Lee CH (2008) Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 7:485-495. (Pubitemid 351729204)
21. Kilgore KS and Billin AN (2008) PPARbeta/delta ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 9:463-469. (Pubitemid 351677899)
22. Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM, Kennett MJ, Gonzalez FJ, and Peters JM (2004) Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 279:23719-23727. (Pubitemid 38685688)
23. Laviolette M, Carreau M, Coulombe R, Cloutier D, Dupont P, Rioux J, Braquet P, and Borgeat P (1988) Metabolism of arachidonic acid through the 5-lipoxygenase pathway in normal human peritoneal macrophages. J Immunol 141:2104-2109.
24. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, and Curtiss LK (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302:453-457. (Pubitemid 37296272)
25. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, et al. (2006) PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103:3444-3449. (Pubitemid 43346488)
26. Li J, Wang J, Nawaz Z, Liu JM, Qin J, and Wong J (2000) Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J 19:4342-4350. (Pubitemid 30623745)
27. Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, Koenig W, Kleemann R, Bakker A, Veenman F, Wahli W, et al. (2004) The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem 279:34411-34420. (Pubitemid 39318067)
28. McDonnell DP, and Wardell SE (2010) The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol 10:620-628.
29. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, et al. (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 154:799-814. (Pubitemid 34292961)
30. Molnar F, Matilainen M, and Carlberg C (2005) Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. J Biol Chem 280:26543-26556. (Pubitemid 41022252)
31. Müller R, Kömhoff M, Peters JM, and Müller- Brüsselbach S (2008a) A Role for PPARβ/δ in Tumor Stroma and Tumorigenesis. PPAR Res 2008:534294.
32. Müller R, Rieck M, and Müller-Brüsselbach S (2008b) Regulation of Cell Proliferation and Differentiation by PPARβ/δ. PPAR Res 2008:614852.
33. Müller-Brüsselbach S, Kömhoff M, Rieck M, Meissner W, Kaddatz K, Adamkiewicz J, Keil B, Klose KJ, Moll R, Burdick AD, et al. (2007) Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient mice. EMBO J 26:3686-3698. (Pubitemid 47236886)
34. Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D, Wahli W, and Desvergne B (2006) Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol 26:3266-3281.
35. Naruhn S, Meissner W, Adhikary T, Kaddatz K, Klein T, Watzer B, Müller-Brüsselbach S, and Müller R (2010) 15- hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor β/δ agonist. Mol Pharmacol 77:171-184.
36. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, Subramanian V, Mukundan L, Ferrante AW, and Chawla A (2008) Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7:496-507. (Pubitemid 351729205)
37. Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, Sk UH, Sharma AK, Amin S, Murray IA, Anderson CR, et al. (2010) Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Mol Pharmacol 78:419-430.
38. Peters JM and Gonzalez FJ (2009) Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. Biochim Biophys Acta 1796:230-241.
39. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, and Gonzalez FJ (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor beta(delta). Mol Cell Biol 20:5119-5128. (Pubitemid 30431565)
40. Rieck M, Meissner W, Ries S, Müller-Brüsselbach S, and Müller R (2008) Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Mol Pharmacol 74:1269-1277.
41. Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, Grillot DA, Iannone MA, Lazar MA, Willson TM, and Billin AN (2008) Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist. Mol Endocrinol 22:523-529. (Pubitemid 351185947)
42. Shearer BG, Wiethe RW, Ashe A, Billin AN, Way JM, Stanley TB, Wagner CD, Xu RX, Leesnitzer LM, Merrihew RV, et al. (2010) Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl) benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist. J Med Chem 53:1857-1861.
43. Shi Y, Hon M, and Evans RM (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA 99:2613-2618. (Pubitemid 34240509)
44. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, and Fruchart JC (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093. (Pubitemid 28512236)
45. Stafslien DK, Vedvik KL, De Rosier T, and Ozers MS (2007) Analysis of ligand-dependent recruitment of coactivator peptides to RXRbeta in a time-resolved fluorescence resonance energy transfer assay. Mol Cell Endocrinol 264:82-89. (Pubitemid 46097305)
46. Stockert J, Adhikary T, Kaddatz K, Finkernagel F, Meissner W, Müller-Brüsselbach S, and Müller R (2011) Reverse crosstalk of TGFβ and PPARβ/δ signaling identified by transcriptional profiling. Nucleic Acids Res 39:119-131.
47. Stumvoll M and Haring HU (2002) Glitazones: clinical effects and molecular mechanisms. Ann Med 34:217-224. (Pubitemid 34804195)
48. Toth PM, Naruhn S, Pape V, Dörr SM, Klebe G, Müller R, and Diederich WE (2011) Development of improved PPARbeta/delta inhibitors. ChemMedChem, in press.
49. Varnat F, Heggeler BB, Grisel P, Boucard N, Corthesy-Theulaz I, Wahli W, and Desvergne B (2006) PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology 131:538-553. (Pubitemid 44160696)
50. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, and DuBois RN (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6:285-295. (Pubitemid 39222041)
51. Weischenfeldt J and Porse B (2008) Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. CSH Protoc 2008: pdb prot5080.
52. Wen YD, Perissi V, Staszewski LM, Yang WM, Krones A, Glass CK, Rosenfeld MG, and Seto E (2000) The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc Natl Acad Sci USA 97:7202-7207. (Pubitemid 30431441)
53. Yu S and Reddy JK (2007) Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta 1771:936-951. (Pubitemid 47198542)
54. Zaveri NT, Sato BG, Jiang F, Calaoagan J, Laderoute KR, and Murphy BJ (2009) A novel peroxisome proliferator-activated receptor delta antagonist, SR13904, has anti-proliferative activity in human cancer cells. Cancer Biol Ther 8:1252-1261.
55. Zoete V, Grosdidier A, and Michielin O (2007) Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 1771:915-925. (Pubitemid 47208545)